Filing Flows › Comparisons › RNAC vs ASBP
Cartesian Therapeutics vs Aspire-Lakewood Holdings: RNAC and ASBP compared
Cartesian Therapeutics is the larger company: $78K of revenue in its latest quarter (Q1 2026) against $63K for Aspire-Lakewood Holdings (Q2 2026).
Where the money goes: RNAC and ASBP
Cartesian Therapeutics (RNAC) · Q1 2026
Cartesian Therapeutics, Q1 2026: revenue $78K (-93% year over year), net loss $39.2M, operating cash flow −$22.1M. The chart follows the revenue to costs, profit and cash.
Aspire-Lakewood Holdings (ASBP) · Q2 2026
Aspire-Lakewood Holdings, Q2 2026: revenue $63K, net loss $1.3M, operating cash flow −$2.1M. The chart follows the revenue to costs, profit and cash.
| Cartesian Therapeutics (RNAC) | Aspire-Lakewood Holdings (ASBP) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q2 2026 |
| Revenue | $78K | $63K |
| Revenue growth, Y/Y | -93% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$39.2M | −$1.3M |
| Operating cash flow | −$22.1M | −$2.1M |
Questions
Which is bigger, Cartesian Therapeutics or Aspire-Lakewood Holdings?
Cartesian Therapeutics is the larger company: $78K of revenue in its latest quarter (Q1 2026) against $63K for Aspire-Lakewood Holdings (Q2 2026).
More: Cartesian Therapeutics earnings · how Cartesian Therapeutics makes money · Aspire-Lakewood Holdings earnings · how Aspire-Lakewood Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Apr 30, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.